This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The major drawbacks of the platinum based anticancer drug, cisplatin, are the serious side effects and acquired drug-resistance, which inevitably increases the drug dosage to patients. Accordingly, a new platinum based anticancer drug that circumvents these clinical inconveniences is strongly desired to improve patient s quality of life (QOL). It is generally believed that cisplatin s anticancer action is triggered by formation of 1,2-intrastrand crosslinks on DNA, resulting in a severe DNA distortion. Most of the structurally related cisplatin-analogues, however, show cross-resistance to cisplatin, probably due to their similar biological consequences. Therefore, we have set up a crystallographic study on a double-stranded DNA, [d(CGCGAATTCGCG)]2, crystallized in the presence of various platinum-based anticancer dr
Showing the most recent 10 out of 167 publications
